Article Text

Authors’ reply
  1. R Jover1,
  2. A Castells2,
  3. X Llor3,
  4. M Andreu4
  1. 1Gastroenterology Department, Hopital General Universitario de Alicante, Alicante, Spain
  2. 2Department of Gastroenterology, Institut de Malaties Digestives, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
  3. 3Germans Trias i Pujol Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
  4. 4Department of Gastroenterology, Hospital del Mar, Barcelona, Spain
  1. Correspondence to:
    R Jover
    Gastroenterology Department, Hospital General Universitario de Alicante, C/Pintor Baeza, sn 03010 Alicante, Spain; jover_rod{at}

Statistics from

We thank Iacopetta and Watanabe for their interest in our paper (Gut 2006;55:1671–2). We do not agree, however, with their conclusions. There is important evidence in the recent literature that supports a relative lack of efficacy for 5-fluorouracil (5-FU) in patients with mismatch repair (MMR)-deficient tumours, with several studies reaching similar conclusions.1–4 In our study, we did not find major differences in patients with MMR-deficient tumours in survival or disease-free survival regarding adjuvant treatment, especially when we compared those results with the ones obtained in patients with MMR-proficient tumours. Although we acknowledge that we had only 53 patients with MMR-deficient tumours, our …

View Full Text

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.